Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :676
Small font sizeDefault font sizeIncrease font size
Navigate here
  Next article
  Previous article 
  Table of Contents
Resource links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (38 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

  In this article

 Article Access Statistics
    PDF Downloaded226    
    Comments [Add]    

Recommend this journal


Year : 2008  |  Volume : 45  |  Issue : 2  |  Page : 72

Need for the appraisal of uncommon side effects of a commonly prescribed drug- Imatinib

1 Department of Medical Oncology, Yashoda Hospitals, Hyderabad, India
2 Department of Pathology, Osmania Medical College, Hyderabad, India
3 Department of Medicine, IMS, BHU, Varanasi, UP, India

Correspondence Address:
VSS Attili
Department of Medical Oncology, Yashoda Hospitals, Hyderabad,
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0019-509X.41775

Rights and Permissions

How to cite this article:
Attili V, Anuradha V, Raju S. Need for the appraisal of uncommon side effects of a commonly prescribed drug- Imatinib. Indian J Cancer 2008;45:72

How to cite this URL:
Attili V, Anuradha V, Raju S. Need for the appraisal of uncommon side effects of a commonly prescribed drug- Imatinib. Indian J Cancer [serial online] 2008 [cited 2021 May 6];45:72. Available from: https://www.indianjcancer.com/text.asp?2008/45/2/72/41775

Dear Sir,

The concept of targeted therapy is emerging as an innovative, high potential new trend in cancer therapy. These drugs are not supposed to affect the normal cells and act selectively on cancer cells there by minimizing the systemic side-effects. However the results are not as expected. One of such novel drugs (first of its kind to be approved by FDA) is Imatinib, a Bcr-Abl tyrosine kinase inhibitor. It has been used in patients of chronic myeloid leukemia and Gastro Intestinal Stromal Tumor (GIST) and has been under evaluation for many more indications. It is usually well tolerated, with relatively minor toxicities like fluid retention and skin changes. However, with the time, oncologists are noticing newer side effects which were not reported in the initial phases of drug trials. The more recently reported ones are, Ototoxicity, [1] cardio toxicity [2] and optic neuritis. [3] It is probably due to the mitochondrial dysfunction as hypothesized by Grazette et al , in their in vitro studies. [4] This entity requires further attention as majority of the patients receiving therapy are relatively young, the therapy often leads to long disease-free survival and the toxicity [mitochondrial damage leading to cardio toxicity and neurotoxicity] results in considerable morbidity.

  References Top

1.Attili VS, Bapsy PP, Anupama G, Lokanatha D. Irreversible sensorineural hearing loss due to Imatinib. Leuk Res 2008;32:991-2.  Back to cited text no. 1  [PUBMED]  [FULLTEXT]
2.Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al . Cardiotoxicity of the cancer therapeutic agent Imatinib mesylate. Nat Med 2006;12:908-16.   Back to cited text no. 2    
3.Govind Babu K, Attili VS, Bapsy PP Anupama G. Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia. Int Ophthalmol 2007;27:43-4.  Back to cited text no. 3    
4.Grazette LP, Kerkela R, Patten R. Imatinib mesylate (Gleevec) induces mitochondrial dysfunction and caspase activation in cardiac myocytes. J Card Fail 2005;11:S126.  Back to cited text no. 4    


Print this article  Email this article
Previous article Next article


  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow